JP2013528591A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528591A5
JP2013528591A5 JP2013509260A JP2013509260A JP2013528591A5 JP 2013528591 A5 JP2013528591 A5 JP 2013528591A5 JP 2013509260 A JP2013509260 A JP 2013509260A JP 2013509260 A JP2013509260 A JP 2013509260A JP 2013528591 A5 JP2013528591 A5 JP 2013528591A5
Authority
JP
Japan
Prior art keywords
methyl
alkyl
oxo
indazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509260A
Other languages
English (en)
Japanese (ja)
Other versions
JP5864546B2 (ja
JP2013528591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035340 external-priority patent/WO2011140325A1/en
Publication of JP2013528591A publication Critical patent/JP2013528591A/ja
Publication of JP2013528591A5 publication Critical patent/JP2013528591A5/ja
Application granted granted Critical
Publication of JP5864546B2 publication Critical patent/JP5864546B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509260A 2010-05-07 2011-05-05 インダゾール Expired - Fee Related JP5864546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33231210P 2010-05-07 2010-05-07
US61/332,312 2010-05-07
PCT/US2011/035340 WO2011140325A1 (en) 2010-05-07 2011-05-05 Indazoles

Publications (3)

Publication Number Publication Date
JP2013528591A JP2013528591A (ja) 2013-07-11
JP2013528591A5 true JP2013528591A5 (enExample) 2015-08-06
JP5864546B2 JP5864546B2 (ja) 2016-02-17

Family

ID=44904073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509260A Expired - Fee Related JP5864546B2 (ja) 2010-05-07 2011-05-05 インダゾール

Country Status (5)

Country Link
US (2) US8846935B2 (enExample)
EP (1) EP2566328B1 (enExample)
JP (1) JP5864546B2 (enExample)
ES (1) ES2534804T3 (enExample)
WO (1) WO2011140325A1 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170736T1 (hr) * 2010-05-07 2017-07-28 Glaxosmithkline Llc Indoli
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトezh2の阻害剤、およびその使用方法
EP2646020B1 (en) * 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2570125A1 (en) 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
CN103987842A (zh) * 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
EP2773754B1 (en) 2011-11-04 2016-08-03 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds for use in the treatment of T-cell mediated diseases
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780013A4 (en) * 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2812001B1 (en) * 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2867282C (en) 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
PL3184523T3 (pl) * 2012-04-13 2019-12-31 Epizyme Inc Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US20150164910A1 (en) * 2012-06-15 2015-06-18 The Regents Of The University Of Califonia Antiviral compounds and methods of use
EP2900653A1 (en) * 2012-09-28 2015-08-05 Pfizer Inc. Benzamide and heterobenzamide compounds
BR112015008447A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
WO2014100463A1 (en) 2012-12-19 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014100665A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2910873A1 (en) * 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
JP2016523955A (ja) 2013-07-10 2016-08-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited Zesteホモログ2エンハンサー阻害剤
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP4324525A3 (en) 2013-10-16 2024-07-17 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
WO2015077194A1 (en) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
CN105017221B (zh) * 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
US9758517B2 (en) * 2014-09-17 2017-09-12 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN107105651A (zh) * 2014-11-06 2017-08-29 达纳-法伯癌症研究所股份有限公司 Ezh2抑制剂及其用途
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) * 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US11059817B2 (en) 2015-09-23 2021-07-13 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
EP4309738A3 (en) * 2015-10-06 2024-07-17 Epizyme, Inc. Method of treating medulloblastoma with an ezh2 inhibitor
HRP20192209T1 (hr) 2015-11-19 2020-07-24 Jiangsu Hengrui Medicine Co., Ltd. Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini
KR102852334B1 (ko) 2016-02-10 2025-09-01 웨이크 포리스트 유니버시티 헬스 사이언시즈 간 섬유화의 모델 시스템 및 그의 제조 및 사용 방법
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
CN107573327B (zh) * 2016-07-05 2020-03-31 四川大学 吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途
KR102351782B1 (ko) * 2016-09-07 2022-01-17 상하이 하이헤 파마수티컬 컴퍼니 리미티드 피리도 5원 방향족 고리계 화합물, 이의 제조 방법 및 용도
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
EP3441388A1 (en) 2016-11-11 2019-02-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 4,5,6-tri-substituted indazoles derivatives, preparation thereof, and use thereof in medicines
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
TWI772424B (zh) 2017-05-18 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種苯并呋喃類衍生物游離鹼的晶型及製備方法
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
JP7295105B6 (ja) 2017-11-10 2023-07-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 ベンゾフラン誘導体の製造方法
TWI698238B (zh) 2017-11-14 2020-07-11 美商輝瑞股份有限公司 Ezh2抑制劑組合治療
CN110016014B (zh) * 2018-01-08 2023-02-17 中国科学院上海药物研究所 Ezh2抑制剂及其制备和抗肿瘤治疗中的应用
FI4043466T3 (fi) 2018-01-31 2024-10-30 Mirati Therapeutics Inc Prc2:n estäjiä
CN110229157B (zh) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 嘧啶并五元芳香杂环类化合物、其制备方法及用途
CZ308400B6 (cs) * 2018-04-11 2020-07-29 Univerzita Karlova Farmaceutický přípravek pro léčení maligního melanomu
CA3104209A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP7411256B2 (ja) 2018-07-27 2024-01-11 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 多置換ベンゼン環化合物、製造方法及びその用途
CN112638823B (zh) * 2018-08-24 2023-11-28 上海特瑞思材料科技有限公司 水过滤膜装置和制备方法
JP7624404B2 (ja) 2019-04-22 2025-01-30 ミラティ セラピューティクス,インク. Prc2阻害剤としてのナフチリジン誘導体
WO2020247475A1 (en) 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法
EP4392034A1 (en) 2021-08-25 2024-07-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
CN116768857A (zh) * 2022-03-09 2023-09-19 中国药科大学 Ezh2/hdac双靶点抑制剂及其制备方法和医药用途
AU2023239344A1 (en) 2022-03-23 2024-10-10 Ideaya Biosciences, Inc. Piperazine substituted indazole compounds as inhibitors of parg
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
TW202528308A (zh) * 2023-09-20 2025-07-16 美商愛德亞生物科學公司 Parg抑制劑
CN117362277B (zh) * 2023-10-13 2025-02-11 沈阳药科大学 含咪唑啉酮结构的苯甲酰胺类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178964A1 (en) * 1999-05-19 2002-02-13 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2004112719A2 (en) 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2009012312A1 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
US8008327B2 (en) * 2008-04-29 2011-08-30 Boehringer Ingelheim International Gmbh Indazole compounds as CCR1 receptor antagonists
CN102369204A (zh) 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
HRP20170736T1 (hr) 2010-05-07 2017-07-28 Glaxosmithkline Llc Indoli
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Similar Documents

Publication Publication Date Title
JP2013528591A5 (enExample)
JP2013527173A5 (enExample)
JP2013544840A5 (enExample)
JP2013525498A5 (enExample)
CA2798622A1 (en) Indoles
AU2003252011B8 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
JP6759100B2 (ja) 治療用阻害化合物
AU2006200437B2 (en) Substituted alkylamine derivatives and methods of use
EA016028B1 (ru) Конденсированные гетероциклические производные и их применение
JP2010513444A5 (enExample)
MXPA04007970A (es) Compuestos de tiazolil urea para el tratamiento de cancer.
TW200536851A (en) Compounds and methods of use
AU2011272198A1 (en) Novel nicotinamide derivatives or salts thereof
JP2015501784A5 (enExample)
JP2015025014A (ja) キナーゼ阻害剤として有用な2−アミノピリジン誘導体
AU2002248340A1 (en) Substituted alkylamine derivatives and methods of use
KR20080112202A (ko) Pi-3 키나제 억제제 및 그것의 사용 방법
EP1835934A2 (en) Enzyme modulators and treatments
CN104583194A (zh) 作为nampt抑制剂的哒嗪和吡啶衍生物
KR20150007349A (ko) Nampt 억제제
US20250179013A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
JP2020512401A5 (enExample)
TWI335325B (en) Substituted alkylamine derivatives and methods of use
CN120603827A (zh) 新型杂环化合物